A global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions
Xellia is a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.
Headquartered in Copenhagen, Denmark, and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1400 employees globally, including state-of-the-art manufacturing sites in China, Denmark, and Hungary. Our strong market position is built on more than 120 years of pharmaceutical industry experience.
Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics’ sector.
Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Our success and strong market position is built on more than 120 years’ of pharmaceutical industry experience.
Supplying products to more than 80 countries worldwide and with more than 500 customers internationally, Xellia Pharmaceuticals places a high regard on maintaining strong relationships with its customers.
Our sales team serves as the first point of contact for customers, ensuring fast and accurate delivery of product information; through managing orders to delivery. Xellia Pharmaceuticals’ Global Business Operations Team serves as the main point of contact for customers to provide them with specialized support for all technical matters that may be associated with market entry and launch of products.
Working collaboratively with the sales team and cross-functionally with Xellia’s internal departments at all sites, Xellia Pharmaceuticals is dedicated to providing reliable outstanding service to its customers at all times.